{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:04:49Z","timestamp":1793228689034,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10147-025-02922-y","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T14:33:20Z","timestamp":1763217200000},"page":"141-150","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Vonoprazan, potassium-competitive acid blocker, on Atezolizumab plus Bevacizumab efficacy in patients with hepatocellular carcinoma: a multicenter retrospective study"],"prefix":"10.1007","volume":"31","author":[{"given":"Masaya","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9183-0760","authenticated-orcid":false,"given":"Katsuyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawako","family":"Uchida-Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzuka","family":"Sasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Yamase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daichiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuika","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Shibano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Arie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadafumi","family":"Hoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Takata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoshi","family":"Odagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisakazu","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichi","family":"Fumita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Otori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"issue":"8","key":"2922_CR1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/hepr.13905","volume":"53","author":"T Hatanaka","year":"2023","unstructured":"Hatanaka T, Kakizaki S, Hiraoka A et al (2023) Association of proton pump inhibitor and antibiotic use with the clinical outcomes of hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: a multicenter analysis. Hepatol Res 53(8):737\u2013748. https:\/\/doi.org\/10.1111\/hepr.13905","journal-title":"Hepatol Res"},{"key":"2922_CR2","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"2922_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070","volume":"1","author":"GK Abou-Alfa","year":"2022","unstructured":"Abou-Alfa GK, Lau G, Kudo M et al (2022) Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. N Engl J Med Evid 1:EVIDoa2100070. https:\/\/doi.org\/10.1056\/EVIDoa2100070","journal-title":"N Engl J Med Evid"},{"key":"2922_CR4","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","volume":"405","author":"T Yau","year":"2025","unstructured":"Yau T, Galle PR, Decaens T et al (2025) Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet 405:1851\u20131864. https:\/\/doi.org\/10.1016\/S0140-6736(25)00403-9","journal-title":"Lancet"},{"key":"2922_CR5","doi-asserted-by":"publisher","first-page":"1326097","DOI":"10.3389\/fimmu.2023.1326097","volume":"14","author":"R Qin","year":"2023","unstructured":"Qin R, Jin T, Xu F (2023) Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma. Front Immunol 14:1326097. https:\/\/doi.org\/10.3389\/fimmu.2023.1326097","journal-title":"Front Immunol"},{"key":"2922_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167230","volume":"1870","author":"X Liu","year":"2024","unstructured":"Liu X, Li S, Wang L et al (2024) Microecological regulation in HCC therapy: gut microbiome enhances ICI treatment. Biochim Biophys Acta Mol Basis Dis 1870:167230. https:\/\/doi.org\/10.1016\/j.bbadis.2024.167230","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2922_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","volume":"11","author":"DS Strand","year":"2017","unstructured":"Strand DS, Kim D, Peura DA (2017) 25 years of proton pump inhibitors: a comprehensive review. Gut Liver 11:27\u201337. https:\/\/doi.org\/10.5009\/gnl15502","journal-title":"Gut Liver"},{"key":"2922_CR8","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1053\/j.gastro.2022.06.070","volume":"163","author":"N Nagata","year":"2022","unstructured":"Nagata N, Nishijima S, Miyoshi-Akiyama T et al (2022) Population-level metagenomics uncovers distinct effects of multiple medications on the human gut microbiome. Gastroenterology 163:1038\u20131052. https:\/\/doi.org\/10.1053\/j.gastro.2022.06.070","journal-title":"Gastroenterology"},{"issue":"22","key":"2922_CR9","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.3748\/wjg.v25.i22.2706","volume":"25","author":"G Bruno","year":"2019","unstructured":"Bruno G, Zaccari P, Rocco G et al (2019) Proton pump inhibitors and dysbiosis: current knowledge and aspects to be clarified. World J Gastroenterol 25(22):2706\u20132719. https:\/\/doi.org\/10.3748\/wjg.v25.i22.2706","journal-title":"World J Gastroenterol"},{"key":"2922_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1070076","volume":"14","author":"S Lopes","year":"2023","unstructured":"Lopes S, Pabst L, Dory A et al (2023) Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis. Front Immunol 14:1070076. https:\/\/doi.org\/10.3389\/fimmu.2023.1070076","journal-title":"Front Immunol"},{"issue":"1","key":"2922_CR11","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1124\/jpet.110.170274","volume":"335","author":"Y Hori","year":"2010","unstructured":"Hori Y, Imanishi A, Matsukawa J et al (2010) 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 335(1):231\u2013238. https:\/\/doi.org\/10.1124\/jpet.110.170274","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"2922_CR12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1080\/17474124.2021.1984878","volume":"16","author":"V Savarino","year":"2022","unstructured":"Savarino V, Antonioli L, Fornai M et al (2022) An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. Expert Rev Gastroenterol Hepatol 16(5):401\u2013410. https:\/\/doi.org\/10.1080\/17474124.2021.1984878","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2922_CR13","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1136\/gutjnl-2016-313312","volume":"66","author":"T Otsuka","year":"2017","unstructured":"Otsuka T, Sugimoto M, Inoue R et al (2017) Influence of potassium-competitive acid blocker on the gut microbiome of Helicobacter pylori-negative healthy individuals. Gut 66:1723\u20131725","journal-title":"Gut"},{"key":"2922_CR14","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1007\/s10147-025-02805-2","volume":"30","author":"M Takahashi","year":"2025","unstructured":"Takahashi M, Nakatsukasa H, Shibano M et al (2025) Potassium-competitive acid blocker has more negative impacts on clinical outcomes in patients with non-small cell lung cancer treated with checkpoint inhibitors than those of proton pump inhibitors. Int J Clin Oncol 30:1582\u20131592. https:\/\/doi.org\/10.1007\/s10147-025-02805-2","journal-title":"Int J Clin Oncol"},{"key":"2922_CR15","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1038\/s41598-024-53158-1","volume":"14","author":"K Iida","year":"2024","unstructured":"Iida K, Naiki T, Etani T et al (2024) Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma. Sci Rep 14:2520. https:\/\/doi.org\/10.1038\/s41598-024-53158-1","journal-title":"Sci Rep"},{"key":"2922_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000531377","volume":"13","author":"M Kudo","year":"2024","unstructured":"Kudo M, Ueshima K, Saeki I et al (2024) A phase 2, prospective, multicenter, single-arm trial of transarterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable intermediate-stage hepatocellular carcinoma: TACTICS-L trial. Liver Cancer 13:99\u2013112. https:\/\/doi.org\/10.1159\/000531377","journal-title":"Liver Cancer"},{"key":"2922_CR17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1159\/000529996","volume":"12","author":"M Kudo","year":"2023","unstructured":"Kudo M, Finn RS, Cheng A-L et al (2023) Albumin-bilirubin grade analyses of atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: A post hoc analysis of the Phase III IMbrave150 study. Liver Cancer 12:479\u2013493. https:\/\/doi.org\/10.1159\/000529996","journal-title":"Liver Cancer"},{"issue":"2","key":"2922_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0281459","volume":"18","author":"K Maesaka","year":"2023","unstructured":"Maesaka K, Sakamori R, Yamada R et al (2023) Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. PLoS ONE 18(2):e0281459. https:\/\/doi.org\/10.1371\/journal.pone.0281459","journal-title":"PLoS ONE"},{"issue":"4","key":"2922_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.2042","volume":"7","author":"H Ohama","year":"2024","unstructured":"Ohama H, Hiraoka A, Tada T et al (2024) Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma. Cancer Rep 7(4):e2042. https:\/\/doi.org\/10.1002\/cnr2.2042","journal-title":"Cancer Rep"},{"key":"2922_CR20","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"2922_CR21","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"A-L Cheng","year":"2022","unstructured":"Cheng A-L, Qin S, Ikeda M et al (2022) Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 76:862\u2013873. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.030","journal-title":"J Hepatol"},{"issue":"4","key":"2922_CR22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.5009\/gnl240085","volume":"18","author":"BG Song","year":"2024","unstructured":"Song BG, Goh MJ, Kang W et al (2024) Analysis of factors predicting the real-world efficacy of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma. Gut Liver 18(4):709\u2013718. https:\/\/doi.org\/10.5009\/gnl240085","journal-title":"Gut Liver"},{"key":"2922_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000302","volume":"7","author":"V Joerg","year":"2023","unstructured":"Joerg V, Scheiner B, D Alessio A et al (2023) Efficacy and safety of atezolizumab\/bevacizumab in patients with HCC after prior systemic therapy: a global, observational study. Hepatol Commun 7:e0302. https:\/\/doi.org\/10.1097\/HC9.0000000000000302","journal-title":"Hepatol Commun"},{"issue":"11","key":"2922_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112927","volume":"15","author":"N Tanabe","year":"2023","unstructured":"Tanabe N, Saeki I, Aibe Y et al (2023) Early prediction of response focused on tumor markers in atezolizumab plus bevacizumab therapy for hepatocellular carcinoma. Cancers (Basel) 15(11):2927. https:\/\/doi.org\/10.3390\/cancers15112927","journal-title":"Cancers (Basel)"},{"key":"2922_CR25","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1002\/jgh3.12932","volume":"7","author":"Y Yano","year":"2023","unstructured":"Yano Y, Yamamoto A, Mimura T et al (2023) Factors associated with the response to atezolizumab\/bevacizumab combination therapy for hepatocellular carcinoma. JGH Open 7:476\u2013481. https:\/\/doi.org\/10.1002\/jgh3.12932","journal-title":"JGH Open"},{"issue":"5","key":"2922_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101364","volume":"7","author":"R Kohya","year":"2025","unstructured":"Kohya R, Suda G, Ohara M et al (2025) Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCC. JHEP Rep 7(5):101364. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101364","journal-title":"JHEP Rep"},{"key":"2922_CR27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/jcph.2402","volume":"64","author":"J Lu","year":"2024","unstructured":"Lu J, Lin X, Teng H et al (2024) Atezolizumab plus bevacizumab versus lenvatinib for hepatocellular carcinoma: a systematic review and meta-analysis. J Clin Pharmacol 64:643\u2013651. https:\/\/doi.org\/10.1002\/jcph.2402","journal-title":"J Clin Pharmacol"},{"key":"2922_CR28","doi-asserted-by":"publisher","first-page":"12204","DOI":"10.1073\/pnas.0909122107","volume":"107","author":"JL Round","year":"2010","unstructured":"Round JL, Mazmanian SK (2010) Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. Proc Natl Acad Sci U S A 107:12204\u201312209. https:\/\/doi.org\/10.1073\/pnas.0909122107","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2922_CR29","doi-asserted-by":"publisher","DOI":"10.1177\/17588359211010937","volume":"13","author":"T Jun","year":"2021","unstructured":"Jun T, Ozbek U, Dharmapuri S et al (2021) Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma. Ther Adv Med Oncol 13:17588359211010936. https:\/\/doi.org\/10.1177\/17588359211010937","journal-title":"Ther Adv Med Oncol"},{"key":"2922_CR30","doi-asserted-by":"publisher","first-page":"1040424","DOI":"10.3389\/fmolb.2022.1040424","volume":"9","author":"F Shoji","year":"2022","unstructured":"Shoji F, Yamaguchi M, Okamoto M et al (2022) Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer. Front Mol Biosci 9:1040424. https:\/\/doi.org\/10.3389\/fmolb.2022.1040424","journal-title":"Front Mol Biosci"},{"key":"2922_CR31","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2147\/JHC.S315696","volume":"8","author":"Y-C Shen","year":"2021","unstructured":"Shen Y-C, Lee P-C, Kuo Y-L et al (2021) An exploratory study for the association of gut microbiome with efficacy of immune checkpoint inhibitor in patients with hepatocellular carcinoma. J Hepatocell Carcinoma 8:809\u2013822. https:\/\/doi.org\/10.2147\/JHC.S315696","journal-title":"J Hepatocell Carcinoma"},{"key":"2922_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.schres.2023.03.005","volume":"255","author":"Z Li","year":"2023","unstructured":"Li Z, Qing Y, Cui G et al (2023) Shotgun metagenomics reveals abnormal short-chain fatty acid-producing bacteria and glucose and lipid metabolism of the gut microbiota in patients with schizophrenia. Schizophr Res 255:59\u201366. https:\/\/doi.org\/10.1016\/j.schres.2023.03.005","journal-title":"Schizophr Res"},{"issue":"4","key":"2922_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2895","volume":"3","author":"M Nomura","year":"2020","unstructured":"Nomura M, Nagatomo R, Doi K et al (2020) Association of short-chain fatty acids in the gut microbiome with clinical response to treatment with nivolumab or pembrolizumab in patients with solid cancer tumors. JAMA Netw Open 3(4):e202895. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.2895","journal-title":"JAMA Netw Open"},{"key":"2922_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111619","volume":"139","author":"R Mirzaei","year":"2021","unstructured":"Mirzaei R, Afaghi A, Babakhani S et al (2021) Role of microbiota-derived short-chain fatty acids in cancer development and prevention. Biomed Pharmacother 139:111619. https:\/\/doi.org\/10.1016\/j.biopha.2021.111619","journal-title":"Biomed Pharmacother"},{"key":"2922_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s44276-023-00008-8","volume":"1","author":"C Hes","year":"2023","unstructured":"Hes C, Jagoe RT (2023) Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle. BJC Reports 1:1\u20139. https:\/\/doi.org\/10.1038\/s44276-023-00008-8","journal-title":"BJC Reports"},{"key":"2922_CR36","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.3390\/cancers15133268","volume":"15","author":"I Robinson","year":"2023","unstructured":"Robinson I, Hochmair MJ, Schmidinger M et al (2023) Assessing the performance of a novel stool-based microbiome test that predicts response to first line immune checkpoint inhibitors in multiple cancer types. Cancers (Basel) 15:3268. https:\/\/doi.org\/10.3390\/cancers15133268","journal-title":"Cancers (Basel)"},{"key":"2922_CR37","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001878","author":"T Fujii","year":"2024","unstructured":"Fujii T, Kuzuya T, Kondo N et al (2024) Altered intestinal Streptococcus anginosus and 5\u03b1-reductase gene levels in patients with hepatocellular carcinoma and elevated Bacteroides stercoris in atezolizumab\/bevacizumab non-responders. J Med Microbiol. https:\/\/doi.org\/10.1099\/jmm.0.001878","journal-title":"J Med Microbiol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02922-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02922-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02922-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:51:21Z","timestamp":1767592281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02922-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["2922"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02922-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no Conflicts of Interests for this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Human Subjects Review Committee of Osaka Metropolitan University (No. 2024-131). Permission to conduct the study was obtained from each facility. The need for informed consent was waived by the Human Subjects Review Committee of each hospital due to the retrospective nature of the study, and the participants were free to opt out if they no longer wished to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}